U.S. FDA approves Biogen's oral MS drug, Tecfidera

Source: PharmaManufacturing.com

Mar 28, 2013

Reuters

On Wednesday, U.S. regulators approved Tecfidera, a new multiple sclerosis drug made by Biogen Idec Inc. It is widely expected to become the No. 1 oral treatment for the disease, with annual sales topping $3 billion. Tecfidera activates a chemical pathway in the body known as Nrf2 that helps protect nerve cells from damage and inflammation. Biogen said it will launch the drug within the coming days. Read the full story.
Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments